[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2001061007A3 - Fibroblast growth factor-23 molecules and uses thereof - Google Patents

Fibroblast growth factor-23 molecules and uses thereof Download PDF

Info

Publication number
WO2001061007A3
WO2001061007A3 PCT/US2001/004778 US0104778W WO0161007A3 WO 2001061007 A3 WO2001061007 A3 WO 2001061007A3 US 0104778 W US0104778 W US 0104778W WO 0161007 A3 WO0161007 A3 WO 0161007A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
polypeptides
fibroblast growth
fgf
molecules
Prior art date
Application number
PCT/US2001/004778
Other languages
French (fr)
Other versions
WO2001061007A2 (en
WO2001061007A9 (en
Inventor
Roland Luethy
Robert Yang
Sidney Suggs
Ildiko Sarosi
Original Assignee
Amgen Inc
Roland Luethy
Robert Yang
Sidney Suggs
Ildiko Sarosi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Roland Luethy, Robert Yang, Sidney Suggs, Ildiko Sarosi filed Critical Amgen Inc
Priority to EP01914373A priority Critical patent/EP1257645A2/en
Priority to JP2001560377A priority patent/JP2005508131A/en
Priority to CA002398603A priority patent/CA2398603A1/en
Priority to AU39767/01A priority patent/AU3976701A/en
Priority to MXPA02007619A priority patent/MXPA02007619A/en
Publication of WO2001061007A2 publication Critical patent/WO2001061007A2/en
Publication of WO2001061007A3 publication Critical patent/WO2001061007A3/en
Publication of WO2001061007A9 publication Critical patent/WO2001061007A9/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides Fibroblast Growth Factor-23 (FGF-23) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGF-23 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGF-23 polypeptides.
PCT/US2001/004778 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecules and uses thereof WO2001061007A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01914373A EP1257645A2 (en) 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecules and uses thereof
JP2001560377A JP2005508131A (en) 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecule and uses thereof
CA002398603A CA2398603A1 (en) 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecules and uses thereof
AU39767/01A AU3976701A (en) 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecules and uses thereof
MXPA02007619A MXPA02007619A (en) 2000-02-15 2001-02-15 Fibroblast growth factor 23 molecules and uses thereof.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18244200P 2000-02-15 2000-02-15
US60/182,442 2000-02-15
US19890300P 2000-04-20 2000-04-20
US60/198,903 2000-04-20
US74858101A 2001-02-15 2001-02-15
US09/748,581 2001-02-15

Publications (3)

Publication Number Publication Date
WO2001061007A2 WO2001061007A2 (en) 2001-08-23
WO2001061007A3 true WO2001061007A3 (en) 2002-03-14
WO2001061007A9 WO2001061007A9 (en) 2002-04-18

Family

ID=27391551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004778 WO2001061007A2 (en) 2000-02-15 2001-02-15 Fibroblast growth factor-23 molecules and uses thereof

Country Status (6)

Country Link
EP (1) EP1257645A2 (en)
JP (1) JP2005508131A (en)
AU (1) AU3976701A (en)
CA (1) CA2398603A1 (en)
MX (1) MXPA02007619A (en)
WO (1) WO2001061007A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531583A (en) * 2000-03-08 2003-10-28 カイロン コーポレイション Human FGF-23 gene and gene expression product
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
ES2340662T3 (en) 2000-07-19 2010-06-08 Advanced Research And Technology Institute FIBROBLAST GROWTH FACTOR (FGF23) NEW PROCEDURE FOR USE.
EP1310554B1 (en) 2000-08-11 2010-05-26 Kyowa Hakko Kirin Co., Ltd. Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
WO2002088358A2 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
AU2003202472B2 (en) * 2001-12-28 2009-11-26 Kyowa Kirin Co., Ltd. Antibodies against fibroblast growth factor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
MX342553B (en) * 2008-04-29 2016-10-04 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods.
JP6254524B2 (en) 2011-07-01 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド Compositions, uses and methods for the treatment of metabolic disorders and diseases
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10369199B2 (en) 2013-10-28 2019-08-06 Ngm Biopharmaceuticals, Inc. Methods of using variants of FGF19 polypeptides for the treatment of cancer
HRP20200881T1 (en) 2014-01-24 2020-09-04 Ngm Biopharmaceuticals, Inc. BETA-KLOTHO DOMAIN 2 BINDING ANTIBODIES AND PROCEDURES FOR THEIR USE
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (en) 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Pharmaceutical compositions containing peptide versions, and methods of using them
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
JP2017537926A (en) 2014-12-04 2017-12-21 ノバルティス アーゲー Methods and compositions using KLOTHO variant polypeptides
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027100A1 (en) * 1997-11-25 1999-06-03 Genentech, Inc. Fibroblast growth factor-19
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
WO2000073454A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001049740A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027100A1 (en) * 1997-11-25 1999-06-03 Genentech, Inc. Fibroblast growth factor-19
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
WO2000073454A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001049740A1 (en) * 2000-01-05 2001-07-12 Zymogenetics, Inc. Novel fgf homolog zfgf12

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMHUM EMBL Heidelberg, Germany; 12 July 1999 (1999-07-12), MUZNY D ET AL.: "Homo sapiens 12p13 BAC RPCI11-388F6", XP002177850 *
See also references of EP1257645A2 *

Also Published As

Publication number Publication date
EP1257645A2 (en) 2002-11-20
CA2398603A1 (en) 2001-08-23
MXPA02007619A (en) 2002-12-13
JP2005508131A (en) 2005-03-31
AU3976701A (en) 2001-08-27
WO2001061007A2 (en) 2001-08-23
WO2001061007A9 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2001061007A3 (en) Fibroblast growth factor-23 molecules and uses thereof
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
WO2001072957A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2002000724A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2001079444A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2002020762A3 (en) Tnf receptor-like molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2003024991A3 (en) Tall-1 receptor molecules and uses thereof
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
WO2002000723A3 (en) Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2003055980A3 (en) Il-17 like molecules and uses thereof
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2002083736A3 (en) G-protein coupled receptor molecules and uses thereof
WO2002044379A3 (en) Transforming growth factor-beta-related molecules and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 39767/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2398603

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007619

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 560377

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001914373

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001914373

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001914373

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)